The lack of clinically applicable mucosal adjuvants is a major hurdle in designing effective mucosal vaccines. We hereby report that the calcium-binding protein S100A4, which regulates a wide range of biological functions, is a potent mucosal adjuvant in mice for co-administered antigens, including the SARS-CoV-2 spike protein, with comparable or even superior efficacy as cholera toxin but without causing any adverse reactions. Intranasal immunization with recombinant S100A4 elicited antigen-specific antibody and pulmonary cytotoxic T cell responses, and these responses were remarkably sustained for longer than 6 months. As a self-protein, S100A4 did not stimulate antibody responses against itself, a quality desired of adjuvants. S100A4 prolonged nasal residence of intranasally delivered antigens and promoted migration of antigen-presenting cells. S100A4-pulsed dendritic cells potently activated cognate T cells. Furthermore, S100A4 induced strong germinal center responses revealed by both microscopy and mass spectrometry, a novel label-free technique for measuring germinal center activity. Importantly, S100A4 did not induce olfactory bulb inflammation after nasal delivery, which is often a safety concern for nasal vaccination. In conclusion, S100A4 may be a promising adjuvant in formulating mucosal vaccines, including vaccines against pathogens that infect via the respiratory tract, such as SARS-CoV-2.
The COVID-19 pandemic, caused by the virus SARS-CoV-2, continues to be a major global health menace. As vaccination is considered the most cost-effective strategy for the control of infectious diseases, strategies to control the COVID-19 pandemic by developing effective vaccination modalities have been intensely developed worldwide. To date the vast majority of available vaccines for human use are needle injection-based, with a few exceptions for a few licensed mucosal vaccines that include oral vaccines for polio, cholera, typhoid, and rotavirus diarrhea, as well as an intranasal vaccine for influenza.1 Likewise, all the SARS-CoV-2 vaccines currently liscenced for human use are injection-based2 despite the fact that SARS-CoV-2 accesses the body through the mucosal membranes of mainly the respiratory tract, at which sites the mucosal adaptive immune responses for preventing pathogen entry are in general more efficiently induced by topical-mucosal rather than parenteral vaccination.3 In particular, nasal immunization is effective for inducing immune responses in the respiratory tract.4 Moreover, mucosal vaccination obviates the use of needles, which is suitable for mass vaccination during pandemics such as COVID-19.
However, a hurdle for a wider use of mucosal vaccination is that with most purified antigens, successful immunization will usually require co-administration with an effective mucosal adjuvant. There is, as yet, a scarcity of safe and effective mucosal adjuvants for human use. Cholera toxin (CT) is the most potent and best characterized “gold standard” mucosal adjuvant used in experiments on animals but is too toxic for humans. We have recently identified a critical role for the calcium-binding protein S100A4 in the mucosal adjuvanticity of CT by demonstrating that endogenous S100A4 is required for CT’s ability to adjuvant both humoral and cellular adaptive immune responses following mucosal immunization.5 Mice that were genetically deficient in S100A4 mounted severely compromised antigen-specific immune responses, which were associated with dampened antigen presentation by dendritic cells (DCs), reduced T cell activation, and a lack of germinal center formation. Notably, the engraftment of wild-type DCs in the S100A4-deficient mice prior to mucosal immunization with the antigen, together with CT, almost fully restored the defective immune responses, indicating that the expression of S100A4 by DCs and possibly other antigen-presenting cells is critical for mounting an effective adaptive immune response.5
S100A4 is one of more than 20 calcium-binding proteins collectively categorized as the S100 protein family.6 S100A4 was originally described as fibroblast-specific protein 1 (FSP1) because of its restricted expression to stromal fibroblasts.7 However, this protein was later found to have a much wider expression spectrum, being expressed also by at least endothelial cells, smooth muscle cells, lymphocytes, neutrophils, macrophages, and DCs.8,9,10 S100A4 interacts with cellular targets through at least two receptors: the receptor for advanced glycation end-products (RAGE) and toll-like receptor 4 (TLR4).11,12 S100A4 has the capacity to regulate a diverse range of cellular processes, such as cell growth, survival, differentiation, and motility.13 We have previously revealed a critical role of S100A4 in adaptive immune responses.5,14
In this study, we examined the potential of using purified exogenous S100A4 as a mucosal adjuvant in its own right for co-administered antigens. Our results demonstrate that when given intranasally, together with either ovalbumin (OVA), as an experimental vaccine antigen, or the spike protein of SARS-CoV-2, as a clinically applicable vaccine antigen, S100A4 can, without any adverse reactions, effectively augment antigen-specific humoral immune responses both mucosally and systemically, as well as stimulate antigen-specific cytotoxic T cell responses in the lungs, to levels comparable to or better than those using CT as adjuvant. Remarkably, these antigen-specific adaptive immune responses were sustained for longer than 6 months. We also introduced a novel, label-free matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) technique for the detection of S100A4-induced germinal center responses in the spleen.
Exogenous S100A4 is a strong mucosal adjuvant
Based on our previous findings of endogenous S100A4 being critical for the in vitro antigen-presenting capacity of DCs, and for the in vivo mucosal adjuvant effect of CT,5 we wished to examine whether exogenous S100A4 might also work as a mucosal adjuvant in its own right. We tested this by immunizing mice intranasally on three occasions with a model antigen, OVA, administered with or without S100A4, and for comparison in a separate group of mice also with CT, and by examining immune responses 3 days after the last dose (Supplementary Fig. 1a). Serum anti-OVA total IgG, IgG1, and IgG2c levels were all robustly augmented after immunization together with S100A4, to levels comparable to those achieved using CT as adjuvant (Supplementary Fig. 1b). S100A4 also potentiated mucosal antibody production in mucosal tissues, resulting in strongly enhanced OVA-specific IgA, total IgG, and IgG1 antibody levels in lung exudate (Supplementary Fig. 1c). Importantly, the intranasal co-administration with S100A4 further resulted in enhanced antigen-specific IgA and IgG responses at a remote site, the vaginal mucosal surface (Supplementary Fig. 1d), consistent with previous studies showing a nasal-genital tract mucosal immunological link.15 Similar to the serum antibody responses, the immunization with S100A4 also promoted mucosal antigen-specific antibody production to levels comparable to those achieved by using CT as adjuvant (Supplementary Fig. 1).
Next, we largely repeated this experiment but halved the amount of S100A4 (10 μg per dose) and extended the antibody measurement to as long as 196 days (roughly 6.5 months) after the last immunization (Fig. 1a). At this substantially late time point, serum anti-OVA IgG antibody responses, including total IgG, IgG1, and IgG2c, remained high in S100A4-adjuvanted mice, not much less compared to a much earlier time point, 10 days after the last dose of immunization (Fig. 1b). Furthermore, mucosal anti-OVA IgG and IgA levels, in lung exudate (Fig. 1c), broncho-alveolar lavage fluid (BALF) (Fig. 1d), vaginal lavage (Fig. 1e), and feces (Fig. 1f), remained substantially high at this late time point in mice which received OVA admixed to S100A4. The S100A4-driven antibody sustainability was comparable to CT-adjuvanted immunization (Fig. 1b‒f). These late time point mucosal antibody levels were also found to be sustained in comparison to the levels in previous experiments measured at an earlier time point (Supplementary Fig. 1c, d), despite a higher dose of S100A4 being used in that immunization (20 μg per dose).
We also determined the accumulation of OVA257-264 peptide (SIINFEKL)-specific CD8 T cells in various tissues using the H-2Kb-SIINFEKL tetramer analyzed by flow cytometry (Supplementary Fig. 2). Co-administration with S100A4 promoted the expansion of CD8 T cells that recognized the MHC class I-associated SIINFEKL peptide in the lung (Fig. 1g), lymph node (Fig. 1h), and spleen (Fig. 1i) at 10 days after the last immunization. A trend of enhanced expansion of these T cells in the lymph nodes and spleen was observed when comparing the effect of S100A4 with CT (Fig. 1h, i). For SIINFEKL peptide-specific T cell expansion in the lung, we also measured at 196 days after the last immunization, and S100A4-adjuvanted immunization maintained the response better than CT (Fig. 1g). These findings suggest that S100A4 could be helpful in driving cytotoxic T cell responses, in addition to stimulating humoral immunity, and may exert a critical role in maintaining protective immunity against viral infections.
To examine if the mucosal adjuvant activity of S100A4 on the immune response to the model antigen OVA would extend to a clinically relevant vaccine antigen, such as the spike protein of SARS-CoV-2 (“Spike”), we immunized mice with Spike alone or together with either S100A4 or CT as adjuvants using a similar intranasal immunization regimen as with OVA (Fig. 2a). Again, co-immunization with S100A4 resulted in substantially increased levels of Spike-specific total IgG and IgG1 antibodies in serum (Fig. 2b), as well as Spike-specific mucosal IgA responses in BALF (Fig. 2c), lung parenchyma (Fig. 2d), nasal mucosa (Fig. 2e), and eye mucosa (Fig. 2f). It has recently been reported that respiratory tract mucosal IgA exerts major neutralizing activity against SARS-CoV-2.16,17
S100A4 extends nasal residence time and promotes tissue transport of antigens
Nasal mucociliary clearance is a mechanism that limits the nasal residence time of vaccine antigens delivered intranasally,18 thus compromising mucosal antigen uptake. Efficient cell-mediated antigen transport to tissues and secondary lymphoid organs is critical to achieving vaccine efficacy.19 We performed in vivo real-time fluorescence optical imaging to monitor the kinetic biodistribution of intranasally administered fluorescently labeled OVA, either in the absence or presence of S100A4. Ventral and dorsal images of live mice were captured at various time points up until 6 h after the administration of Alexa Fluor 647-conjugated OVA (OVA-AF647). Shortly after the intranasal administration of OVA-AF647, identical ventral view fluorescence signals were observed at the snouts of mice (5 min; Fig. 3a; ventral view). No fluorescence signals were detected from the dorsal side at this time point, probably due to blocking of the signal by the overlying turbinate bone. As can be clearly observed ventrally, the fluorescent signal persisted more robustly in the snouts of the mice that received the fluorescently labelled antigen together with S100A4, suggesting a longer nasal residence time of the antigen (Fig. 3a, b).
Furthermore, co-administration with S100A4 enhanced the dorsal appearance of the fluorescence signals associated with tissues around the spleen, which started to appear at 30 min, peaked at around 4 h, and declined at 6 h post-antigen delivery (Fig. 3a; dorsal view). We then euthanized the mice at about 6 h after antigen delivery and removed the skin at the left side of the abdominal cavity in order to get clearer views of the fluorescence deposition in relevant organs. The co-administration with S100A4 clearly promoted the accumulation of fluorescent OVA in the spleen, stomach, and kidney (Fig. 3c). In particular, the spleen demonstrated the most remarkable S100A4-driven antigen accumulation, as the mouse that received only fluorescent OVA showed merely the background fluorescence (Fig. 3c). For both the nasal retention and tissue accumulation of the fluorescent OVA, S100A4 demonstrated stronger effects than the CT used for comparison (Fig. 3a‒c).
Next, we collected nasal tissues, cervical lymph nodes and lung tissues from each individual mouse at 6 h after the delivery of fluorescent OVA and prepared single-cell suspensions to investigate, using flow cytometry, the distribution of the fluorescent OVA at the cellular level including the CD103+ migratory DCs.20 Co-administration with S100A4 profoundly promoted accumulation of migrating DC (CD45+CD103+CD11c+MHC IIhigh/int)- and macrophage (CD45+F4/80+)-associated fluorescent OVA in the nasal tissue (Fig. 3d), cervical lymph nodes (Fig. 3e), and lung tissue (Fig. 3f). Of note, the antigen-associated DCs identified in the nasal tissue had a lower expression level of MHC class II. In contrast, MHC class IIhigh DCs did not carry fluorescent OVA (Supplementary Fig. 3a). CT only increased the cell-associated OVA accumulation in the lungs (Fig. 3f), but not nose (Fig. 3d) and lymph nodes (Fig. 3e) at 6 h after antigen delivery. At 12 h after OVA delivery, even more potent effects of S100A4 on the accumulation of antigen-loaded antigen-presenting cells in the lungs could be revealed, while CT showed at least a trend of weaker effects at this time point compared with S100A4 (Supplementary Fig. 3b). Efficient uptake and transport of vaccine antigens have been described as a critical quality for assessing the adjuvant activity.21
Using in vitro cultured bone marrow-derived DC (BMDC), we failed to observe any augmentation in the uptake of fluorescent OVA after treatment with either S100A4 or CT (Supplementary Fig. 4a). Similarly, uptake of fluorescent OVA by fresh ex vivo cells from the nasal tissue, cervical lymph nodes, and spleen was not enhanced by S100A4 or CT (Supplementary Fig. 4b). Thus, it is likely S100A4 promoted the migration of antigen-presenting DCs from the nasal mucosa but did not promote antigen uptake itself. Our data showing S100A4-promoted antigen accumulation in the nasal tissue, cervical lymph nodes and lung tissues after nasal delivery of the antigen (Fig. 3d‒f) support a stimulatory effect of S100A4 in promoting the migration of antigen-presenting cells including DCs and macrophages that had captured the antigen after mucosal delivery. It has been previously reported that S100A4 is critical for regulating the motility of macrophages.9 We also observed the distribution of S100A4 in the lung tissues and spleen 24 h after intranasal inoculation (Supplementary Fig. 5), which supports the long-distance function of S100A4.
To fundamentally confirm the effect of S100A4 on DC migration, we designed an adoptive transfer assay to unambiguously demonstrate more efficient DC migration driven by S100A4. Control and S100A4-primed BMDCs were labelled with a green fluorescent dye for easy tracking. Following injection of the fluorescent DCs into the mouse footpad, substantially increased numbers of S100A4-primed DCs arrived in the draining lymph nodes compared with the control DC (Fig. 3g).
S100A4 effectively induces germinal center responses after intranasal immunization
The development of germinal centers is a recognized mechanism for the generation of high-quality antibodies after immunization.22,23 We harvested mouse spleens and cervical lymph nodes after intranasal immunization for flow cytometric analysis of the impact of S100A4 on immune cell activation, including the germinal center response, using the gating strategy defined in Supplementary Fig. 6. Frequencies of activated non-germinal center B cells (CD69+CD38+B220+)24 were increased in both the spleen and cervical lymph nodes of mice that received the antigen together with S100A4 (Fig. 4a). In both compartments, S100A4 also expanded germinal center B cells (GL7+FAS+CD38–B220+) (Fig. 4b) and T follicular helper cells (PD-1+CXCR5+CD4+Foxp3–), a cell type which is critical in the formation of germinal centers (Fig. 4c). The immune enhancing effects of S100A4 were similar to those of CT (Fig. 4a‒c). These results were confirmed using immune staining and confocal microscopy to demonstrate the typical germinal center morphology. Mouse spleens were first cryosectioned, followed by immunofluorescent staining for the expression of B220, GL7, as well as the cell proliferation marker Ki-67, as previously reported.5 Immunization with S100A4 strongly promoted the expansion of GL7+ and Ki-67+ B cells and morphological changes associated with germinal center formation (Fig. 4d).
S100A4-adjuvanted intranasal immunization promotes lipid accumulation in the spleen
It has recently been reported that germinal center B cells require active oxidation of fatty acids instead of glycolysis to meet the energetic challenge of rapid cell proliferation.25 In order for efficient germinal center development to take place, hosts need to mobilize lipid transport to the germinal centers. Therefore, we examined the accumulation of lipids using MALDI-TOF MS after S100A4-adjuvanted immunization. A variety of lipids, with glycerolipids and glycerophospholipids being the dominant forms, were identified in the spleens (Supplementary Fig. 7). A shotgun lipidomics approach was used to analyze all lipid classes together. The abundance of total lipids was increased in the spleen after co-immunization with S100A4 (Fig. 5a). The lipid intensities were quantified and expressed using an intensity box plot which displayed a remarkable increase of lipids in spleens from S100A4-adjuvanted mice (Fig. 5b). Principal component analysis (PCA) revealed a complete separation of S100A4-adjuvanted immunization from both the OVA only immunization and the naïve mouse controls (Fig. 5c). A similar and more intense lipid accumulation response than that induced by S100A4 was seen in mice given CT together with OVA (Fig. 5).
As our germinal center activity investigation using various approaches was based on the same cohort of mice, we compared the lipid accumulation and the expression of GL7, an established germinal center marker, in individual mice. Good correlations were established between the expression of GL7 using flow cytometry and fluorescence microscopy and the lipid abundance determined using MALDI-TOF (Supplementary Fig. 8), supporting the usefulness of lipid abundance as a surrogate marker for the germinal center response.
Extracellular S100A4 potentiates DC activation
DCs are critical antigen-presenting cells that bridge innate and adaptive immune responses and, as such, are rational targets for the choice of effective adjuvants.26 We have previously demonstrated that adoptive engraftment of wild-type DCs could restore the defective adaptive immune responses of S100A4-deficient mice.5 Here we examined the regulatory effect of exogenous S100A4 on cultured DCs. Our data clearly demonstrates that mRNA expression of a group of cytokines and molecules with immune regulatory activities was upregulated in BMDCs following incubation with S100A4 (Fig. 6a). Specifically, the transcript levels of a number of cytokines that are critical to adaptive immunity, including IL-1β, IL-2, IL-6, and IL-10, were augmented after treatment with S100A4, as were co-stimulatory molecules, including CD80, CD86, and CD40. Furthermore, at the protein level, S100A4 was found to potently activate BMDCs by augmenting the production of these co-stimulatory molecules, as well as IL-1β and IL-6 (Fig. 6b).
We have previously shown a dependence on NFκB signaling as a critical DC activation pathway used by CT to exert mucosal adjuvant activity.27 Here, we can also demonstrate that S100A4-mediated DC activation is at least partially dependent on NFκB signaling. Thus, S100A4-induced production of IL-1β, a critical molecule in the pathway of adjuvanticity, was substantially suppressed in NFκB–/– BMDCs, although the increased expression of CD80 and CD86 by S100A4 remained intact in NFκB–/– cells (Fig. 6c). The latter finding may suggest that S100A4 could have a broader spectrum of signaling pathways than CT, which failed to increase both co-stimulatory molecule expression and IL-1β production in NFκB–/– BMDCs (Fig. 6c). Extracellular S100A4 has been shown to activate NFκB in various types of cells.11,28,29 Therefore, it is not surprising that S100A4, as shown here, also stimulates DCs through the NFκB pathway.
It is reported that S100A4 triggers intracellular signaling pathways through RAGE and TLR4.30 Indeed, BMDCs expressed both RAGE and TLR4 (Fig. 6d), and we found that RAGE expression was upregulated by exogenous S100A4 (Fig. 6e). We then tested whether S100A4-mediated DC activation would require either or both of these two receptors. To this end, BMDCs were incubated with S100A4 either in the presence or absence of FPS-ZM1, an inhibitor of RAGE, or TAK-242, an inhibitor of TLR4, and the effects on CD86 expression as well as production of IL-1β were measured. The results showed that S100A4-induced upregulation of both of these activation markers was almost completely abrogated by blocking either RAGE or TLR4 (Fig. 6f), suggesting the requirement of both receptors for S100A4-induced DC activation.
Extracellular S100A4 enhances MHC class I antigenic peptide cross-presentation by DC and activation of cytotoxic T cells
We have demonstrated the potent effect of S100A4 in stimulating cytotoxic CD8 T cells against a co-administered antigen (Fig. 1g‒i). Next, we wished to also confirm that S100A4 could enhance MHC class I-associated antigenic peptide cross-presentation on DCs, a critical step in the activation of cytotoxic T cell responses after immunization with protein-based subunit vaccines.31 To this end, we incubated OVA-pulsed DCs either in the presence or absence of S100A4, followed by co-culturing the DCs with RF33.70 hybridoma T cells that had T cell receptors (TCRs) specific for OVA257-264 presented by H-2Kb. S100A4-pulsed DCs substantially augmented the activation of T cells as measured by IL-2 production (Fig. 6g). S100A4 demonstrated a more potent effect compared with CT (Fig. 6g).
The adjuvanticity of S100A4 is not affected by contaminating lipopolysaccharide (LPS)
We performed both in vivo immunization and in vitro DC activation assays to rule out the possible confounding effect of a residual low amount of endotoxin present in the recombinant S100A4 product (10 pg LPS per μg S100A4, as measured using a Limulus amebocyte lysate assay). In vivo, mice were given three intranasal immunizations at ten-day intervals with OVA in the presence of various doses of S100A4 or various amounts of LPS corresponding to the residual LPS amount in a given S100A4 dose. Ten days after the last immunization, blood was collected and OVA-specific total IgG antibody production in serum was measured. The tested range of LPS amounts failed to promote OVA-specific IgG production, supporting that the enhancement of this response by S100A4 is a true adjuvant effect of S100A4 but not the result of contaminating LPS (Supplementary Fig. 9a). On the other hand, as a positive control, LPS at 1 μg (5000-fold of the highest contamination level) effectively promoted the anti-OVA response (Supplementary Fig. 9a).
In the in vitro experiments, we incubated BMDCs with LPS at 10 pg/ml, i.e., the estimated contamination level of LPS in 1 μg/ml S100A4, which was tested in parallel, and observed no enhancement in the expression of the genes under study (Supplementary Fig. 9b). In contrast, a 100,000-fold higher level of LPS (1 μg/ml) demonstrated potent stimulatory effects (Supplementary Fig. 9b). Further support for the S100A4 protein, but not the residual endotoxin contamination, being the entity responsible for DC activation came from studies showing that the strong promotion of CD80, CD86 and IL-1β in BMDCs by the recombinant S100A4 was largely suppressed by a neutralizing antibody against S100A4 (Supplementary Fig. 9c).
S100A4 does not induce humoral immune responses against itself after intranasal immunization and does not induce inflammation of the olfactory bulb
In vaccination practice, an ideal adjuvant should be able to support different vaccine antigens in multiple administrations, so that the adjuvant can be formulated in different vaccine preparations for subsequent innoculation. Therefore, immune responses against the adjuvant itself should preferably be avoided. To assess the quality of S100A4 in this respect, we repeated our basic intranasal immunization model using OVA as an experimental antigen admixed with either S100A4 or CT as an adjuvant (Supplementary Fig. 10a). Consistent with the previous findings (e.g., Supplementary Fig. 1b and Fig. 1b), we again showed that both S100A4 and CT were able to remarkably augment anti-OVA IgG levels (Supplementary Fig. 10b, c). Interestingly, while CT, as a foreign protein, stimulated substantial levels of anti-CT IgG antibody responses (Supplementary Fig. 10c), S100A4 failed to stimulate anti-S100A4 IgG antibody production above the level seen in naïve mice (Supplementary Fig. 10b). This could be due to the fact that S100A4 is an internal protein subject to immune tolerance. The data suggests that S100A4 could lead to improved tolerability over non-host proteins (e.g., CT) in repeated use as a vaccine adjuvant.
It is generally believed that adjuvant with neurotoxicity may affect olfactory bulbs through retrograde axonal transport from the olfactory epithelium, resulting in the inflammatory responses in the olfactory bulb, and this may disrupt the normal functionality of the central nervous system.32 Thus, we stained for the leukocyte infiltration in the olfactory bulb, a sign of inflammation. Compared with CT which caused substantial leukocyte accumulation in the olfactory bulb, S100A4 did not induce such inflammatory responses (Supplementary Fig. 11a). Consistently, we could show that S100A4 did not trigger increases in flammatory cytokines including IL-6 and IL-12 in the olfactory bulb after intranasal immnunization (Supplementary Fig. 11b). Taken together, these data preliminarily support a good safety profile of S100A4 at least with respect to olfactory bulb inflammation.
The search for clinically applicable mucosal adjuvants still remains a challenging endeavor. By virtue of their strong cAMP mobilization capacity, both CT and heat-labile enterotoxin (LT) from Escherichia coli have been used as experimental mucosal adjuvants. Although for safety reasons, these toxins are not suitable as mucosal adjuvants in humans,33 CT has been extensively studied and is considered the “gold standard” experimental mucosal adjuvant.34 Therefore, CT is commonly used as a benchmark for comparing the adjuvant effects of other candidate mucosal adjuvants. Various approaches have been attempted to modify these native bacterial toxins to derive mutants that can be used clinically.35 Yet, toxin-independent approaches are also worth exploring. In this study, we present experimental evidence that nasal immunization with protein antigens adjuvanted with S100A4 induced adaptive immune responses comparable, or superior, in magnitude to those achieved using CT as an adjuvant. S100A4 augmented antigen-specific immune responses, both systemically and at mucosal surfaces, to intranasally co-administered antigens without any adverse effects, as shown using both OVA as a model antigen and the SARS-CoV-2 spike protein as a clinically relevant vaccine antigen. Furthermore, S100A4 potently induced the expansion of antigen-specific CD8 T cells, which could persist in lung tissues for at least six and a half months after immunization, similar to the persistence of the high titers of antigen-specific antibodies in various compartments. The fact that exogenous S100A4 was demonstrated to effectively prolong mucosal antigen retention, mobilize DC and macrophage migration, promote germinal center responses, and activate cytotoxic T cells, supports the proposed usefulness of this molecule as a mucosal adjuvant.
S100A4 is a member of the damage-associated molecular pattern (DAMP) family.36 This heterogeneous family is composed of proteins, lipids, nucleic acids, and small-molecule compounds that are normally sequestered inside cells but are released upon stress stimulation, e.g., tissue injury.37 DAMP molecules have been implicated in the activation of inflammasomes,38 a process used by many adjuvants.39 We have previously demonstrated that DCs from mice lacking S100A4 have compromised inflammasome-associated caspase-1 and IL-1β production upon treatment with CT.5 In the present study, we show that extracellular S100A4 can promote not only the upregulation of critical co-stimulatory molecules in DCs, including CD80, CD86, and CD40, but also the production of key cytokines, including IL-1β, for the induction and maintenance of adaptive immunity. The generation of IL-1β by DCs and other APCs as a consequence of NFκB activation and an inflammasome response has been found to be a critical step in the adjuvant function of CT.27 Taken together, our work suggests not only an endogenous effect of S100A4 in mucosal immunization,5 but also that, as a secreted protein,29 S100A4 may have a paracrine or endocrine function on cells including APCs, which is likely further enhanced by the exogenous S100A4 added as an adjuvant.
In addition to the possible induction of mucosal tolerance, poor uptake and rapid clearance by mucociliary movement of the antigen at the nasal mucosal surface have been described as hurdles for developing effective nasal immunization strategies.18 Various types of mucoadhesive agents have been co-administered with the antigens to improve nasal retention and antigen uptake.40 Chitosan, as a biocompatible and biodegradable natural polymer, has been extensively investigated as an effective mucoadhesive for improving nasal vaccine delivery.41 Interestingly, as shown here, S100A4, in addition to its potent immune stimulatory effect, remarkably prolonged the nasal residence time of co-administered fluorescent OVA. This effect is likely due to the calcium-binding activity of S100A4, since free calcium is critical for maintaining the ciliary beating frequency,42 and restricted ciliary beating may lead to a prolonged antigen residence time. In addition to prolonging the mucosal antigen retention time, our data also suggests that S100A4 can promote DC migration from the nasal mucosa. The latter effect may depend on the ability of S100A4 to both increase and engage RAGE on DCs, insofar as it has been previously observed that DCs depend on RAGE for their in vivo homing to lymph nodes.43 Furthermore, expression of S100A4 has been demonstrated to be required for the development of mature microfold cells in Peyer’s patches.44 If exogenous S100A4 can promote the expansion or activity of microfold cells in the nasal mucosa, this may also account for the adjuvant activity of S100A4 in nasal immunization.
We further demonstrated that nasal co-administration of an antigen with S100A4 strongly promoted germinal center formation in both draining lymph nodes and the spleen. It is in the germinal center that high-affinity B cells and long-lived plasma cells are formed,45,46 and their clonal expansion involves vigorous energy-demanding cell proliferation. In turn, this requires an adequate energy supply through activation of relevant metabolic pathways.47,48 Weisel et al. recently demonstrated that proliferating germinal center B cells use fatty acids for energy supply instead of aerobic glycolysis to meet their metabolic requirements.25 This finding indicates that a successful germinal center reaction requires a substantial input of fatty acids which can be generated by lipid metabolism. Prompted by this discovery, we undertook to quantitatively assess lipid accumulation in the spleen in response to adjuvant-enhanced germinal center formation using MALDI-TOF MS. Our results demonstrate that the combined intensity of various lipid species in immunized mice adjuvanted with S100A4 was dramatically increased. Importantly, lipid accumulation in the spleen, as measured by MALDI-TOF, correlated closely with the levels of the established germinal center marker antigen GL7, measured using conventional techniques including flow cytometry and fluorescence microscopy. Taken together, our data suggests that lipid measurement by MALDI-TOF can provide a surrogate marker of germinal center activity. Being a label-free technology, MALDI-TOF could be a valuable tool for quantification of germinal center activity, not least in non-rodent animal models, in which the availability of commercial antibodies for specific germinal center immunostaining is lacking. However, whether or not the lipid responses are essential for the adjuvant nature of S100A4 awaits further investigation.
S100A4 is expressed in many normal cells, including fibroblasts, endothelial cells, smooth muscle cells, and leukocytes.7,8,9,10 Furthermore, S100A4 has been found to be critical in maintaining the normal biological functions of various types of cells through regulating cell growth, survival, differentiation, and motility.13 We note here that clinically-oriented research on S100A4 has largely focused on its cancer metastasis-promoting properties.10,49 However, this does not preclude its applicability as an adjuvant in vaccination, as there is no evidence that exogenous S100A4 can induce cancer metastasis, and, on the contrary, S100A4 is also found to exert anticancer activity.50,51 Importantly, we did not observe any obvious side effects either shortly after or more than 6 months after nasal administration with S100A4. Therefore, we believe that S100A4, as a human endogenous protein, may have an advantageous safety profile compared with microbial pathogen-associated molecular pattern molecules, which have been extensively tested for possible modification as a mucosal adjuvant.52 Notwithstanding this assumption, rigorous safety evaluations must be undertaken before S100A4 can be used clinically as a vaccine adjuvant.
Materials and methods
Wild-type C57BL/6 mice were purchased from B&K Universal AB, Stockholm, Sweden, or bred in-house at the Centralized Animal Facilities at the Hong Kong Polytechnic University. NFκB p50−/− mice on a C57BL/6 background were purchased from the Jackson Laboratory. Female mice were 6–8 weeks old at the start of all experiments. The studies were approved by the Ethical Committee for Laboratory Animals in Gothenburg, Sweden, and the Animal Subjects Ethics Sub-Committee of the Research Committee at the Hong Kong Polytechnic University.
Immunization and collection of specimens
OVA (grade V) was purchased from Sigma-Aldrich. Recombinant mouse S100A4 was purchased from Gentaur Molecular Products. The residual amount of endotoxin in the recombinant S100A4 preparation was examined using a Pierce™ Chromogenic Endotoxin Quant Kit (Thermo Fisher Scientific). Mice were anesthetized using isoflurane prior to immunization. For intranasal immunization, mice received a total of 20 µl (10 μl in each nostrial) phosphate-buffered saline (PBS) containing 10 μg OVA or 5 μg of the spike protein of SARS-CoV-2 (the receptor-binding domain; recombinant product from Sino Biological) mixed with or without 10 μg or 20 μg S100A4 as indicated. In some experiments, LPS (Sigma-Aldrich) (various amounts as indicated) or CT (List Biological Laboratories) (1 μg) were used as control adjuvants. Three different immunization models were constructed based on when samples were harvested for analysis (3, 10, or 196 days). For all three models, three intranasal immunizations were performed, with samples being harvested after the third (final) immunization. Samples included serum, lungs, BALF, nasal lavage, vaginal lavage, eye exudate, fecal extracts, cervical lymph nodes, and spleens.
Antigen-specific antibody measurement
Enzyme-linked immunosorbent assay (ELISA) was employed to measure the titers of antigen-specific antibodies. A 96-well ELISA plate (Thermo Fisher Scientific) was coated with 100 µl OVA (100 µg/ml), the spike protein (2 µg/ml), S100A4 (2 µg/ml), or CT (2 µg/ml), followed by an overnight incubation at 4 °C. After washing and blocking, specimens from immunized or control mice were added after appropriate serial dilution followed by incubation at 37 °C for 2 h. After rigorous washing, the plate was incubated with goat anti-mouse secondary antibodies for IgG (Southern Biotech; 1030-05), IgG1 (Southern Biotech; 1070-05), IgG2c (Southern Biotech; 1079-05), or IgA (Southern Biotech; 1040-05) conjugated with horseradish peroxidase (HRP), followed by standard color development. Absorbance measurements and titer calculation were completed using a BMG SPECTROStar Nano microplate reader.
Cell culture and treatment with S100A4
BMDCs were generated by culturing bone marrow cells in culture medium (RPMI-1640; Sigma-Aldrich) supplemented with 10% fetal bovine serum (Gibco), 1% L-glutamine, 1% gentamicin, and 50 μΜ 2-mercaptoethanol (all from Sigma-Aldrich) in the presence of 200 ng/ml recombinant Flt3L (PeproTech) for 9 days. Cells were incubated in vitro with various stimuli, including CT (0.1 μg/ml), recombinant S100A4 (1 μg/ml), or LPS (10 pg/ml or 1 μg/ml), for specified time periods at 37 °C in 5% CO2, followed by washing and re-suspension in buffer for flow cytometric examination or RNA purification. Where indicated, an anti-S100A4 antibody (clone 6B12)53 or isotype control was used to block functional S100A4 extracellularly. To investigate whether the surface expression of the receptors RAGE and TLR4 were required for S100A4 to activate DCs, BMDCs were incubated overnight with S100A4 or S100A4 pre-mixed with FPS-ZM1 (10 μM; Sigma-Aldrich) or TAK-242 (10 μM; Calbiochem), inhibitors of RAGE and TLR4, respectively. To confirm the role of S100A4 in promoting antigen cross-presentation, BMDC (1 × 105 cells/well) or DC2.4 (a DC cell line; Sigma-Aldrich) (1 × 104 cells/well) were treated with OVA (1 mg/ml) mixed with or without S100A4 (1 μg/ml) or CT (1 μg/ml) overnight. After washing, DCs were co-cultured with RF33.70 cells (1 × 105 cells/ well), a T-T hybridoma with TCR specific for OVA257-264 (SIINFEKL) presented by H-2Kb (a gift from Dr KL Rock)54 at 1:1 (BMDC to RF33.70) or 1:10 (DC2.4 to RF33.70) overnight. Release of IL-2 into supernatant was measured using a commercial ELISA kit (Sigma-Aldrich).
Live mouse imaging
The dorsal skin of mice was shaved to prevent attenuation of the fluorescent signal. Mice were administered intranasally with 20 µl PBS containing 10 μg of OVA-AF647 alone or mixed with 20 μg of S100A4 or 1 μg CT. The fluorescence intensity was immediately measured using an IVIS Lumina Series III pre-clinical in vivo animal imaging system (Perkin Elmer), and the measurement was repeated at various time points for 6 h. Results were analyzed using Living Image 4.7.3 (Perkin Elmer). Naïve mice were used to adjust settings for eliminating background fluorescence.
In vivo dendritic cell migration assay
To investigate DC migration, BMDCs were treated with or without S100A4 (1 μg/ml) overnight and stained with CellTracker™ green (5-chloromethylfluorescein diacetate [CMFDA]; Thermo Fisher Scientific) according to the manufacturer’s instruction. 2 × 106 stained cells were injected into the footpad of naïve 8–12 weeks old C57BL/6 mice and popliteal lymph nodes were harvested after 24 h for flow cytometric analysis.
Flow cytometric analysis
In vitro cultured cells or single cell suspensions from various types of tissues were prepared. For staining of surface markers, cells were incubated with fluorescent antibodies to mouse B220, CD3, CD4, CD11b, CD11c, CD38, CD45, CD69, CD80, CD86, CD40, CD103, GL7, FAS, CXCR5, MHC class II, Ter-119, GR-1, CD19, F4/80 and PD-1 (BD Biosciences or eBioscience). Dead cells were excluded by staining with BD Horizon™ Fixable Viability Stain 620. For measuring intracellular expression of IL-1β, IL-6, or Foxp3, cells were first stained for relevant surface markers as described above, then fixed and permeabilized using the Intracellular Fixation and Permeabilization Buffer Set (BD Biosciences), followed by intracellular staining with antibodies against IL-1β (clone NJTEN3; eBioscience), TNF-α (clone TN3-19.12; eBioscience), or Foxp3 (clone FLK-16; Nordic Biosite). Cell surface expression of the receptors RAGE and TLR4 was determined by staining the cells with anti-RAGE and anti-TLR4 or their respective isotype control antibodies. BV421-conjugated H-2Kb-SIINFEKL tetramer (MBL International) was used for the measurement of CD8 T cells that can recognize OVA257-264 peptide (SIINFEKL) presented by MHC class I. Cells were analyzed using an LSR II or FACSAria III flow cytometer (BD Biosciences). The data were analyzed using FlowJo software (Tree Star).
Mouse spleens were embedded in Cryomatrix™ embedding resin (Thermo Fisher Scientific). Frozen tissues were sectioned at 7 μm thick using CryoStar™ NX70 Cryostat (Thermo Fisher Scientific), then fixed in acetone, air-dried, and rinsed in PBS. Next, spleen cryosections were stained with anti-B220-biotin (BD Biosciences), GL7-Alexa Fluor 488 (eBioscience), and Ki-67-Horizon V450 (BD Biosciences), followed by incubation with Alexa Fluor 594-conjugated streptavidin (Invitrogen). Slides were mounted with ProLong™ gold antifade mounting media (Thermo Fisher Scientific). Confocal images were acquired using a TCS SPE confocal microscope (Leica) with a 60× zoom. The data were analyzed using LAS X Leica software (Leica).
MALDI-TOF MS analysis
Spleen tissues were immediately frozen in liquid nitrogen and stored at −70 °C, followed by sectioning, as described above. Sections were embedded onto an indium tin oxide-coated conductive glass slide and left to dry in a vacuum desiccator overnight. A layer of MALDI matrix [2,5-dihydroxybenzoic acid (30 mg/ml) dissolved in a mixture of 70% acetonitrile and 30% water containing 0.1% trifluoroacetic acid] was applied by aerosol spraying onto the dried slides. Matrix-coated slides were then mounted on the MALDI target adapter after wiping off the matrix from the outer regions of the slide using a tissue wetted with ethanol to ensure optimum electric contact with the adapter. Slides were then analyzed for lipids and fatty acids using an UltrafleXtreme MALDI-TOF mass spectrometer (Bruker). The results were processed using SCiLS Lab 2020 Pro software (Bruker). Principal component analysis (PCA) was used to compare different treatment groups to identify different ranks of variance within a dataset.55
Quantitative reverse transcription PCR (RT-qPCR)
Total RNA was isolated using an RNeasy Mini Kit (Qiagen). cDNA was synthesized using a RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). The generated cDNA was used as a template for RT-qPCR, which was performed with a ViiA™ 7 Real-Time PCR System (Applied Biosystems) using a PowerUp™ SYBR™ Green Master Mix (Thermo Fisher Scientific). PCR was carried out with an initial incubation at 50 °C for 2 min, 95 °C for 2 min, and then 40 cycles of 95 °C for 15 s and 60 °C for 1 min. The specificity of the reaction was verified by melt-curve analysis. The 2−ΔΔCt method was employed to calculate relative gene expression levels. GAPDH was amplified as an internal control. The forward and reverse primers for GAPDH were 5′-GGTGAAGGTCGGTGTGAACGGA-3′ and 5′-TGTTAGTGGGGTCTCGCTCCTG-3′; for IL-1β 5′-GGAGAACCAAGCAACGACAAAATA-3′ and 5′- TGGGGAACTCTGCAGACTCAAAC-3′; for IL-2 5′-CCTGAGCAGGATGGAGAATTACAT-3′ and 5′-TCCAGAACATGCCGCAGAG-3′; for IL-6 5′-CCACTTCACAAGTCGGAGGCTTA-3′ and 5′-CCAGTTTGGTAGCATCCATCATTTC-3′; for IL-10 5′-GCCAGAGCCACATGCTCCTA-3′ and 5′-GATAAGGCTTGGCAACCCAAGTAA-3′; for CD86 5′-TCCTGTAGACGTGTTCCAGA-3′ and 5′-TGCTTAGACGTGCAGGTCAA-3′; for CD80 5′-GGTATTGCTGCCTTGCCGTT-3′ and 5′-TCCTCTGACACGTGAGCATC-3′; for CD40 5′-GTTTAAAGTCCCGGATGCGA-3′ and 5′-CTCAAGGCTATGCTGTCTGT-3′; and for IL-12 5′-TGGGAGTACCCTGACTCCTG-3′ and 5′-GGAACGCACCTTTCTGGTTA-3′.
Mouse spleen, lung and olfactory bulb tissues were fixed in 10% neutral buffered formalin for 24 h at room temperature followed by embedding in paraffin wax. Tissue processing was carried out using a Thermo Scientific Excelsior AS Tissue Processor. Consecutive 5 μm sections were generated from each of the paraffin-embedded tissue blocks using a standard microtome blade and the sections were fixed onto glass microscope slides. The slides were stained with a mouse monoclonal antibody against His-tag (clone 1B7G5; Proteintech) or a rat monoclonal antibody against CD45 (Clone 30-F11; BD Biosciences), followed by staining with a mouse IgG-specific (Proteintech; SA00001-1) or a rat IgG-specific (Cell Signaling Technology; 7077S) HRP-linked secondary antibody, respectively, using the HRP/DAB Detection IHC kit (Abcam; ab64261) according to the manufacturer’s instruction.
A Mann–Whitney U test or Student’s t test was used to calculate statistical differences between different treatment conditions. Comparisons involving multiple groups were performed using two-way ANOVA with Bonferroni’s multiple comparison test. The Kruskal–Wallis test, a non-parametric method, was used for MALDI-TOF data analysis. All the statistical analyses were calculated using Prism software 7. In all the statistical significance comparisons we have provided the exact P values except for those P values < 0.0001.
All data generated or analyzed during this study are included in this published paper [and its supplementary information files].
Miquel-Clopes, A., Bentley, E. G., Stewart, J. P. & Carding, S. R. Mucosal vaccines and technology. Clin. Exp. Immunol. 196, 205–214 (2019).
Bok, K., Sitar, S., Graham, B. S. & Mascola, J. R. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity 54, 1636–1651 (2021).
Su, F., Patel, G. B., Hu, S. & Chen, W. Induction of mucosal immunity through systemic immunization: Phantom or reality? Hum. Vaccin. Immunother. 12, 1070–1079 (2016).
Lobaina Mato, Y. Nasal route for vaccine and drug delivery: features and current opportunities. Int. J. Pharm. 572, 118813 (2019).
Sun, J. B. et al. Deficiency in Calcium-Binding Protein S100A4 Impairs the Adjuvant Action of Cholera Toxin. Front. Immunol. 8, 1119 (2017).
Gross, S. R., Sin, C. G., Barraclough, R. & Rudland, P. S. Joining S100 proteins and migration: for better or for worse, in sickness and in health. Cell. Mol. Life Sci. 71, 1551–1579 (2014).
Strutz, F. et al. Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol. 130, 393–405 (1995).
Boomershine, C. S. et al. Autoimmune pancreatitis results from loss of TGFbeta signalling in S100A4-positive dendritic cells. Gut 58, 1267–1274 (2009).
Li, Z. H., Dulyaninova, N. G., House, R. P., Almo, S. C. & Bresnick, A. R. S100A4 regulates macrophage chemotaxis. Mol. Biol. Cell 21, 2598–2610 (2010).
Mishra, S. K., Siddique, H. R. & Saleem, M. S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence. Cancer Metastasis Rev. 31, 163–172 (2012).
Boye, K., Grotterod, I., Aasheim, H. C., Hovig, E. & Maelandsmo, G. M. Activation of NF-kappaB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes. Int J. Cancer 123, 1301–1310 (2008).
Cerezo, L. A. et al. The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. Rheumatol. (Oxf.) 53, 1520–1526 (2014).
Donato, R. et al. Functions of S100 proteins. Curr. Mol. Med. 13, 24–57 (2013).
Bruhn, S. et al. A generally applicable translational strategy identifies S100A4 as a candidate gene in allergy. Sci. Transl. Med. 6, 218ra4 (2014).
Czerkinsky, C. & Holmgren, J. Topical immunization strategies. Mucosal. Immunol. 3, 545–555 (2010).
Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, eabd2223 (2020).
Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, eabf1555 (2021).
Gizurarson, S. The effect of cilia and the mucociliary clearance on successful drug delivery. Biol. Pharm. Bull. 38, 497–506 (2015).
Irvine, D. J., Aung, A. & Silva, M. Controlling timing and location in vaccines. Adv. Drug Deliv. Rev. 158, 91–115 (2020).
Kedl, R. M. et al. Migratory dendritic cells acquire and present lymphatic endothelial cell-archived antigens during lymph node contraction. Nat. Commun. 8, 2034 (2017).
Liang, F. et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci. Transl. Med. 9, eaal2094 (2017).
Aradottir Pind, A. A. et al. Adjuvants Enhance the Induction of Germinal Center and Antibody Secreting Cells in Spleen and Their Persistence in Bone Marrow of Neonatal Mice. Front. Immunol. 10, 2214 (2019).
Lycke, N. Is the choice of vaccine adjuvant critical for long-term memory development? Expert Rev. Vaccines 9, 1357–1361 (2010).
Oliver, A. M., Martin, F. & Kearney, J. F. Mouse CD38 is down-regulated on germinal center B cells and mature plasma cells. J. Immunol. 158, 1108–1115 (1997).
Weisel, F. J. et al. Germinal center B cells selectively oxidize fatty acids for energy while conducting minimal glycolysis. Nat. Immunol. 21, 331–342 (2020).
Tesfaye, D. Y., Gudjonsson, A., Bogen, B. & Fossum, E. Targeting Conventional Dendritic Cells to Fine-Tune Antibody Responses. Front. Immunol. 10, 1529 (2019).
Terrinoni, M., Holmgren, J., Lebens, M. & Larena, M. Requirement for Cyclic AMP/Protein Kinase A-Dependent Canonical NFkappaB Signaling in the Adjuvant Action of Cholera Toxin and Its Non-toxic Derivative mmCT. Front. Immunol. 10, 269 (2019).
Kim, H. et al. Extracellular S100A4 negatively regulates osteoblast function by activating the NF-kappaB pathway. BMB Rep. 50, 97–102 (2017).
Schmidt-Hansen, B. et al. Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene 23, 5487–5495 (2004).
Bjork, P. et al. Common interactions between S100A4 and S100A9 defined by a novel chemical probe. PLoS ONE 8, e63012 (2013).
Ho, N. I., Huis In ‘t Veld, L. G. M., Raaijmakers, T. K. & Adema, G. J. Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines? Front. Immunol. 9, 2874 (2018).
Fujihashi, K., Koga, T., van Ginkel, F. W., Hagiwara, Y. & McGhee, J. R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20, 2431–2438 (2002).
Lycke, N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12, 592–605 (2012).
Sanchez, J. & Holmgren, J. Cholera toxin - a foe & a friend. Indian J. Med. Res. 133, 153–163 (2011).
Lycke, N. & Lebrero-Fernandez, C. ADP-ribosylating enterotoxins as vaccine adjuvants. Curr. Opin. Pharm. 41, 42–51 (2018).
Bertheloot, D. & Latz, E. HMGB1, IL-1alpha, IL-33 and S100 proteins: dual-function alarmins. Cell Mol. Immunol. 14, 43–64 (2017).
Venereau, E., Ceriotti, C. & Bianchi, M. E. DAMPs from Cell Death to New Life. Front. Immunol. 6, 422 (2015).
Lage, S. L. et al. Emerging Concepts about NAIP/NLRC4 Inflammasomes. Front. Immunol. 5, 309 (2014).
Ivanov, K., Garanina, E., Rizvanov, A. & Khaiboullina, S. Inflammasomes as Targets for Adjuvants. Pathogens 9, 252 (2020).
Jabbal-Gill, I. Nasal vaccine innovation. J. Drug Target 18, 771–786 (2010).
Kang, M. L., Cho, C. S. & Yoo, H. S. Application of chitosan microspheres for nasal delivery of vaccines. Biotechnol. Adv. 27, 857–865 (2009).
Schmid, A. & Salathe, M. Ciliary beat co-ordination by calcium. Biol. Cell 103, 159–169 (2011).
Manfredi, A. A. et al. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J. Immunol. 180, 2270–2275 (2008).
Kunimura, K. et al. S100A4 Protein Is Essential for the Development of Mature Microfold Cells in Peyer’s Patches. Cell Rep. 29, 2823–2834 (2019). e2827.
Suan, D., Sundling, C. & Brink, R. Plasma cell and memory B cell differentiation from the germinal center. Curr. Opin. Immunol. 45, 97–102 (2017).
Shlomchik, M. J. & Weisel, F. B cell primary immune responses. Immunol. Rev. 288, 5–9 (2019).
Jung, J., Zeng, H. & Horng, T. Metabolism as a guiding force for immunity. Nat. Cell Biol. 21, 85–93 (2019).
Waters, L. R., Ahsan, F. M., Wolf, D. M., Shirihai, O. & Teitell, M. A. Initial B Cell Activation Induces Metabolic Reprogramming and Mitochondrial Remodeling. iScience 5, 99–109 (2018).
Boye, K. & Maelandsmo, G. M. S100A4 and metastasis: a small actor playing many roles. Am. J. Pathol. 176, 528–535 (2010).
Dukhanina, E. A., Lukyanova, T. I., Dukhanin, A. S. & Georgieva, S. G. The role of S100A4 protein in anticancer cytotoxicity: its presence is required on the surface of CD(4+)CD(25+)PGRPs(+)S100A4(+) lymphocyte and undesirable on the surface of target cells. Cell Cycle 17, 479–485 (2018).
C, E. L. N. et al. Cancer predisposition in mice deficient for the metastasis-associated Mts1(S100A4) gene. Oncogene 23, 3670–3680 (2004).
Demento, S. L., Siefert, A. L., Bandyopadhyay, A., Sharp, F. A. & Fahmy, T. M. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol. 29, 294–306 (2011).
Klingelhofer, J. et al. Anti-S100A4 antibody suppresses metastasis formation by blocking stroma cell invasion. Neoplasia 14, 1260–1268 (2012).
Rock, K. L., Rothstein, L. & Gamble, S. Generation of class I MHC-restricted T-T hybridomas. J. Immunol. 145, 804–811 (1990).
Shao, C. et al. The Use of Principal Component Analysis in MALDI-TOF MS: a Powerful Tool for Establishing a Mini-optimized Proteomic Profile. Am. J. Biomed. Sci. 4, 85–101 (2012).
We thank Shuwei Liu, Chujun Deng and Chi-Ming Wong, Hong Kong Polytechnic University, for technical support and intellectual advice, and Kenneth Rock, University of Massachusetts, for providing the RF33.70 cell line. We thank the staff at the Centralized Animal Facilities (CAF) and University Research Facility in Life Sciences (ULS) at the Hong Kong Polytechnic University for valuable technical support. This work was supported by the Hong Kong Polytechnic University Internal Research Fund (P0001169), the NSFC/RGC Joint Research Scheme of the Research Grant Council of Hong Kong (N_PolyU533/19), the Health and Medical Research Fund of Hong Kong (20190332), and the National Natural Science Foundation of China (81961160738), PolyU Lean Launchpad Programme, and the Greater Bay Area International Institute for Innovations (GBA I3) Postdoc Programme.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sen Chaudhuri, A., Yeh, YW., Zewdie, O. et al. S100A4 exerts robust mucosal adjuvant activity for co-administered antigens in mice. Mucosal Immunol 15, 1028–1039 (2022). https://doi.org/10.1038/s41385-022-00535-6